ClinicalTrials.Veeva

Menu
L

Liver Institute Northwest | Seattle, WA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cilofexor
Resmetirom
Ursodeoxycholic Acid
Elafibranor
Obeticholic Acid
UDCA
MGL-3196
Volixibat
Pemafibrate
DA-1241

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 33 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Procedure: Liver Biopsy
Drug: MGL-3196

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic ste...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: Placebo
Drug: Efimosfermin

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Active, not recruiting
Primary Sclerosing Cholangitis
Drug: Placebo Matched to Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 120 mg

The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.

Begins enrollment in 2 months
Primary Sclerosing Cholangitis (PSC)
Drug: Placebo
Drug: LB-P8 low-dose

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
PBC
Primary Biliary Cholangitis
Drug: Volixibat
Drug: Placebo

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
Primary Sclerosing Cholangitis
Drug: Placebo
Drug: Volixibat

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: Placebo (NNC0194-0499)
Drug: NNC0174 0833 placebo

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling
Primary Biliary Cirrhosis
Drug: Seladelpar 10 mg Capsule
Drug: Seladelpar 5 mg Capsule

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Enrolling
Primary Biliary Cholangitis
Drug: Seladelpar
Drug: Placebo

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid...

Active, not recruiting
Primary Biliary Cirrhosis
Drug: Placebo
Drug: Elafibranor 80mg

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Cilofexor (CILO)/Firsocostat (FIR)
Drug: PTM SEMA

This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: HM15211
Drug: Placebo of HM15211

Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.

Enrolling
Primary Biliary Cholangitis
Drug: K-808 (Dose A)
Drug: Placebo

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatoh...

Enrolling
NASH
Drug: K-877-ER
Drug: Placebo

Trial sponsors

Gilead Sciences logo
Madrigal Pharmaceuticals logo
Ipsen logo
Kowa logo
Mirum Pharmaceuticals logo
Boston Scientific logo
Celgene logo
CymaBay Therapeutics logo
Enanta Pharmaceuticals logo
Hanmi Pharmaceutical logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems